New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
07:30 EDTMLNXMellanox upgraded to Buy from Hold at Jefferies
Jefferies upgraded Mellanox (MLNX) to Buy after its channel checks indicated the company will benefit from an upgrade cycle with the launch of Intel's (INTC) Grantley server platform. The firm raised its price target for shares to $50 from $37.
News For MLNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
10:01 EDTMLNXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: BlackBerry (BBRY) initiated with a Buy at TD Securities... British American Tobacco (BTI) initiated with a Buy at Berenberg... Cabot Oil & Gas (COG) initiated with a Buy at SunTrust... Celestica (CLS) initiated with a Hold at TD Securities... Devon Energy (DVN) initiated with an Equal Weight at Stephens... Fitbit (FIT) initiated with an Outperform at Oppenheimer... Imperial Tobacco (ITYBY) initiated with a Buy at Berenberg... Kite Pharma (KITE) initiated with an Outperform at RBC Capital... Mellanox (MLNX) initiated with a Buy at Roth Capital.
07:51 EDTMLNXMellanox initiated with a Buy at Roth Capital
Roth Capital analyst Brian Alger initiated Mellanox with a Buy rating and $60 price target. The analyst said Mellanox has a full suite of end to end products serving networking across Ethernet and Infiniband and is well positioned to outpace peers.
January 28, 2016
09:19 EDTMLNXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Facebook (FB), up 13.9%... Under Armour (UA), up 14.6%... MicroStrategy (MSTR), up 8.9%... Harley-Davidson (HOG), up 8%... Paypal (PYPL), up 6%... Mellanox (MLNX), up 7.9%... Cirrus Logic (CRUS), up 6.2%... Alibaba (BABA), up 4.5%. ALSO HIGHER: Neos Therapeutics (NEOS), up 61.4% after the FDA approved Adzenys XR-ODT for the treatment of ADHD... Exelixis (EXEL), up 4.7% after the U.S. FDA determined the company's New Drug Application for cabozantinib is sufficiently complete... Kinder Morgan (KMI), up 6.7% after being upgraded at Credit Suisse and Stifel. DOWN AFTER EARNINGS: OSI Systems (OSIS), down 21.3%... ServiceNow (NOW), down 22.3%... eBay (EBAY), down 11.5%... InvenSense (INVN), down 10.5%... Juniper Networks (JNPR), down 9.3%... Hologic (HOLX), down 4.4%... Abbott Laboratories (ABT), down 3.6%... Potash (POT), down 2.1%... Qualcomm (QCOM), down 3.6%.
January 27, 2016
19:30 EDTMLNXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Facebook (FB), up 11.4%... Mellanox (MLNX), up 6.4%... Paypal (PYPL), up 5%... Crown Castle (CCI), up 2.2%... Citrix (CTXS), up 2.4%... Las Vegas Sands (LVS), up 1%... SanDisk (SNDK), up 1%. ALSO HIGHER: Radius Health (RDUS), up 1.2% after announcing a clinical collaboration with Novartis (NVS)... LinkedIn (LNKD) is up 2.4%, Alphabet (GOOG, GOOGL) is up 2.2% and 2.6%, respectively, Netflix (NFLX) is up 1%, Amazon.com (AMZN) is up 2%, and Twitter (TWTR) is up marginally after Facebook reported quarterly results... MGM Resorts (MGM) is up 2.2% and Wynn Resorts (WYNN) is up 2.2%. DOWN AFTER EARNINGS: ServiceNow (NOW), down 16.5%... eBay (EBAY), down 12.8%... United Rentals (URI), down 9.7%... Juniper Networks (JNPR), down 9.6%... Silicon Graphics (SGI), down 9.1%... Discover Financial (DFS), down 7.4%... InvenSense (INVN), down 6.1%... Core Laboratories (CLB), down 4.3%... Vertex Pharmaceuticals (VRTX), down 1.1%. ALSO LOWER: Incyte (INCY), down 12.8% after announcing that it will halt the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation.
16:17 EDTMLNXMellanox sees Q1 revenue $180M-$185M, consensus $171.35M
16:16 EDTMLNXMellanox reports Q4 EPS 77c, consensus 70c
Reports Q4 revenue $176.9M, consensus $173.91M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use